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Background:  The direct thrombin inhibitor (DTI), bivalirudin, is associated with similar efficacy and superior safety in patients undergoing 
percutaneous coronary intervention. The role of DTIs in carotid artery stenting (CAS) is less well defined.
Methods: We compared the incidence of in-hospital hemorrhagic and in-hospital/30-day ischemic outcomes among patients in the CARE 
Registry® who underwent CAS between May 2005 and March 2011 using bivalirudin or unfractionated heparin (UFH). Propensity score matching was 
used to obtain a balanced cohort of 3070 patients in each group.
Results: Patients treated with bivalirudin had a significantly lower incidence of any bleeding (1.4% vs 2.3%; OR = 0.61, 0.42-0.9; p=0.011), 
bleeding requiring transfusion (0.9% vs 1.8%; OR = 0.50, 0.31-0.79; p=0.003) and stroke (1.7% vs. 2.6%; OR = 0.63; 0.44-0.90; p=0.01) when 
compared with UFH treated patients. At 30 days, bivalirudin was associated with significantly lower rates of stroke (3.5% vs 4.9%, p = 0.014) and 
target vessel revascularization (TVR - endarterectomy - 0.6% vs 1.1%; stenting - 0.8% vs 4.5%). The incidence of in-hospital and 30 day mortality, 
and myocardial infarction was not significantly different between groups (Table 1).
Conclusion: Bivalirudin was associated with lower rates of hemorrhagic and ischemic outcomes compared with UFH during the index 
hospitalization for CAS. At 30 days, stroke and TVR occurred less frequently with bivalirudin than UFH. Randomized comparisons of these agents are 
needed.
